Previous Close | 4.4700 |
Open | 4.4800 |
Bid | 4.2900 x 200 |
Ask | 4.3400 x 200 |
Day's Range | 4.3000 - 4.6592 |
52 Week Range | 1.0800 - 5.0000 |
Volume | |
Avg. Volume | 1,473,078 |
Market Cap | 225.501M |
Beta (5Y Monthly) | 1.70 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9300 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for GTHX
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to t
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27. G1 Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
Q4 2023 G1 Therapeutics Inc Earnings Call